Fortress Biotech (FBIO) Projected to Release Quarterly Earnings on Thursday

Fortress Biotech (NASDAQ:FBIO) is projected to release its Q2 2026 results before the market opens on Thursday, August 13th. Analysts expect the company to post earnings of ($0.20) per share and revenue of $18.30 million for the quarter. Parties may review the information on the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Wednesday, August 12, 2026 at 4:30 PM ET.

Fortress Biotech (NASDAQ:FBIO) last announced its quarterly earnings data on Thursday, May 14th. The biopharmaceutical company reported $2.82 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.22) by $3.04. The firm had revenue of $16.04 million for the quarter, compared to analysts’ expectations of $16.34 million. Fortress Biotech had a net margin of 193.12% and a return on equity of 109.66%.

Fortress Biotech Stock Performance

FBIO stock opened at $2.61 on Wednesday. Fortress Biotech has a twelve month low of $1.90 and a twelve month high of $4.53. The company has a quick ratio of 2.77, a current ratio of 2.86 and a debt-to-equity ratio of 0.18. The company has a market cap of $86.70 million, a P/E ratio of 0.82 and a beta of 1.21. The business’s fifty day moving average is $3.06 and its 200-day moving average is $2.95.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on FBIO. Wall Street Zen upgraded Fortress Biotech from a “buy” rating to a “strong-buy” rating in a report on Sunday, May 24th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Fortress Biotech in a research note on Wednesday, July 8th. Finally, Citigroup reissued a “buy” rating on shares of Fortress Biotech in a research report on Monday, May 18th. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $17.00.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in FBIO. Quadrature Capital Ltd bought a new stake in shares of Fortress Biotech in the 4th quarter valued at about $180,000. Man Group plc acquired a new stake in Fortress Biotech in the 4th quarter valued at about $193,000. Bridgeway Capital Management LLC bought a new position in Fortress Biotech during the fourth quarter worth about $667,000. Panagora Asset Management Inc. grew its holdings in Fortress Biotech by 56.9% during the fourth quarter. Panagora Asset Management Inc. now owns 56,668 shares of the biopharmaceutical company’s stock worth $207,000 after purchasing an additional 20,556 shares during the period. Finally, State Street Corp increased its position in Fortress Biotech by 11.5% during the fourth quarter. State Street Corp now owns 77,266 shares of the biopharmaceutical company’s stock worth $283,000 after buying an additional 8,000 shares during the last quarter. Institutional investors and hedge funds own 96.51% of the company’s stock.

About Fortress Biotech

Fortress Biotech, Inc is a clinical‐stage biopharmaceutical company focused on acquiring, developing and commercializing novel pharmaceutical and biotechnology products. Headquartered in New York, the company operates through a network of majority‐owned subsidiaries that target areas of high unmet medical need, including oncology, rare diseases and dermatology. Fortress Biotech’s business model emphasizes in‐licensing or acquiring promising drug candidates and coordinating their development through specialized affiliate companies, allowing for flexible capital allocation and focused management of individual programs.

Through its portfolio of subsidiaries, Fortress Biotech advances a diversified pipeline spanning small molecules, biologics and cell therapies.